PatientsVille.com Logo

PLATELET COUNT DECREASED and Celexa

PatientsVille

PLATELET COUNT DECREASED Symptoms and Causes

Platelets are little pieces of blood cells. Platelets help wounds heal and prevent bleeding by forming blood clots. Your bone marrow makes platelets. Problems can result from having too few or too many platelets, or from platelets that do not work properly.

If your blood has a low number of platelets, it is called thrombocytopenia. This can put you at risk for mild to serious bleeding. If your blood has too many platelets, you may have a higher risk of blood clots. With other platelet disorders, the platelets do not work as they should. For example, in von Willebrand Disease, the platelets cannot stick together or cannot attach to blood vessel walls. This can cause excessive bleeding.

Treatment of platelet disorders depends on the cause.

NIH: National Heart, Lung, and Blood Institute

Check out the latest treatments for PLATELET COUNT DECREASED

PLATELET COUNT DECREASED treatment research studies

Celexa clinical trials, surveys and public health registries


Find Drug Side Effect reports



Celexa Side Effects

Dizziness (136)
Nausea (135)
Anxiety (127)
Suicidal Ideation (124)
Depression (123)
Headache (120)
Completed Suicide (120)
Pain (111)
Insomnia (109)
Feeling Abnormal (102)
Vomiting (101)
Diarrhoea (99)
Fall (96)
Fatigue (91)
Loss Of Consciousness (89)
Tremor (89)
Dyspnoea (85)
Agitation (78)
Confusional State (76)
Aggression (69)
Asthenia (38)
Convulsion (34)
Suicide Attempt (33)
Condition Aggravated (32)
Abnormal Behaviour (32)
Weight Increased (31)
Somnolence (30)
Anger (30)
Pulmonary Embolism (28)
Malaise (28)
Chest Pain (28)
Crying (27)
Irritability (27)
Abdominal Pain Upper (25)
Abdominal Pain (25)
Constipation (25)
Overdose (25)
Serotonin Syndrome (25)
Paraesthesia (25)
Syncope (24)
Amnesia (24)
Hyperhidrosis (24)
Intentional Self-injury (22)
Hypertension (21)
Arthralgia (21)
Injury (20)
Palpitations (20)
Heart Rate Increased (20)
Blood Pressure Increased (20)
Rash (19)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Can ratio-citalopram be taken long term with Lectopam 6 mg?

Celexa triggered my tourettes syndrome. Three weeks after starting this med, I started having motor and vocal tics. Do not advise anyone to take this drug. It sucks.

I need to find out if Celexa is available in Ecuador as I will be living there for several months. Thanks.

I Took celexa for about 7 years im a 28 year old male. A couple months after getting off of the drug I have been twitching all over my body. Feet, legs,thighs,arms,stomach,hands,face,everywhere. I also have this feeling of a lump stuck in my throat.

It probably didn't trigger your TS. It was probably just supressing symptoms to a point where they were un noticable. Celexa is something they use to help alleviate the symptoms. so when you came off of it, they came back. They could have developed w

Marax was the asthma the best medicine for me to treat asthma. Inhalers do not work. Apparently centuries of using the contents of Marax with success does not count with the FDA. Shame on them. Bring back this medication.

can platelete count reduced drastically to 1000 on medication of sibelium 5 mg for 2 weeks.

I just started taking lisinopril and am also staying very tired. Dizziness and lightheadness are my biggest problems right now.I am taking this with cardura and zoloft, so it may not count here. But i wanted to share my input and after reading the c

had my first shot of aranesp one week ago for anemia , i have renal failure, I'm 62 , and I am a working nurse. I will be getting aranesp every 2 weeks if my blood count is less than 11. well out of no where I have becom

1st day was hell, had about every side effect in the book. 2nd day was better, side effects decreased greatly 5th day is going well so far- feeling a little 'edgy & apprehensive' but better than the alternative

After a few weeks on Piascledine, knee and back pain decreased considerably with no side effects noted. Not perfect, but much better. I was walking like an old man.

After a urinalisis the doctor told me there were no white blood cells, only red blood cells in urine. drew blood and had cat scan and revealed a 7mm kidney stone. but i'm worried about having no white blood cell count in my urine

After consuming myonal for two days, i suffer from jaundice... my bilirubin counts wer of the roof so as my ALP, and ALT count.. hmm...

An addition to Frances Wedderburn's side effects from Januvia, some of my Liver Enzymes became elevated. They decreased when checked 10 days after stopping Januvia. Diarrhoea continues

Been taking Omnic or about 2months and have experienced decreased semen production. Is this a common side effect of taking Omnic or a new symptom of a slightly enlarged prostate? Thanks

PLATELET COUNT DECREASED Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting EScitalopram PIndolol ONset of Action
Condition: Unipolar Depression
Interventions: Drug: escitalopram, pindolol;   Drug: escitalopram
Outcome Measures: MADRS score change between baseline and 2 weeks of treatment;   Response/remission (MADRS) at 6 weeks;   Adverse events;   Correlation of drug level of pindolol and/or escitalopram and clinical outcome (primary outcome) between treatment groups
2 Recruiting Lexapro®'s Efficacy After Dose Escalation in Remission Study
Condition: Major Depressive Disorder
Intervention: Drug: escitalopram
Outcome Measures: Montgomery-Åsberg Depression Rating Scale (MADRS);   Hamilton Depression Rating Scale-17 items (HAM-D);   Hamilton Anxiety Rating Scale (HAM-A);   Clinical Global Impression-severity (CGI-S);   Clinical Global Impression-Improvement (CGI-I);   Beck's Depression Inventory(BDI);   WHO Quality Of Life scale Abbreviated Version(WHOQOL-BREF);   Clinically Useful Depression Outcome Scale (CUDOS);   Short From-36 Health survey (SF-36 Health survey)
3 Unknown  Circadian Effects of Escitalopram
Condition: Depression
Intervention: Drug: placebo/escitalopram
Outcome Measures: Resetting effect of Escitalopram on the circadian pacemaker;   Correlation between improvement in depression with Escitalopram and the degree of realignment between the timing of sleep and the timing of the biological clock.
4 Recruiting Escitalopram, Placebo and tDCS in Depression: a Non-inferiority Trial
Conditions: Major Depressive Disorder;   Major Depressive Disorder, Recurrent, Unspecified;   Major Depressive Disorder, Single Episode, Unspecified
Interventions: Drug: Escitalopram oxalate;   Device: transcranial direct current stimulation
Outcome Measures: Change in Hamilton Rating Scale for Depression, 17 items (HAMD17);   Change in Montgomery-Asberg Depression Rating Scale (MADRS);   Change in Beck Depression Inventory (BDI);   Hamilton Rating Scale for Depression, 17 items (HAMD17)
5 Recruiting Escitalopram Trial for Irritable Bowel Syndrome (IBS) Patients With Panic Disorder
Conditions: Irritable Bowel Syndrome;   Panic Disorder
Intervention: Drug: Escitalopram
Outcome Measures: Gastrointestinal Symptom Rating Scale (GSRS).;   State Trait Anxiety Inventory (STAI).
6 Unknown  Cipralex in Treatment of Depressive Symptoms and Chronic Back Pain
Conditions: Low Back Pain;   Depression
Interventions: Drug: Escitalopram;   Drug: Placebo
Outcome Measures: In comparison to placebo-treated patients, patients with treated with Cipralex report a significant reduction in depressive symptoms (>= 50% HAMD score) after 4 weeks of treatment.;   In comparison to placebo, subjects treated with Cipralex report a significant reduction in pain intensity (>= 50% reduction of pain questionnaire score or VAS) after 12 weeks of treatment.;   In comparison with placebo, subjects treated with Cipralex report a significant improvement in physical and everyday functioning after 12 weeks of treatment.;   Personality traits do not have a significant influence on outcome regarding depressive traits, pain intensity and functioning.;   Personality disorders are significantly influencing worse outcome regarding depressive traits, pain intensity and functioning.
7 Recruiting DECIFER: DEpression and Citalopram In First Episode Recovery
Conditions: Schizophrenia;   Schizophreniform Disorder
Interventions: Drug: Citalopram;   Behavioral: Psychoeducation;   Behavioral: Cognitive Behavioral Therapy (CBT);   Radiation: Functional Magnetic Resonance Imaging (fMRI);   Drug: Placebo
Outcome Measures: Calgary Depression Scale for Schizophrenia (CDSS);   Scale for the Assessment of Negative Symptoms (SANS);   Brief Psychiatric Rating Scale (BPRS);   InterSePT Scale for Suicidal Thinking (ISST);   Heinrich Quality of Life Scale (QOL)
8 Not yet recruiting Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)
Condition: Major Depressive Disorder (MDD)
Interventions: Drug: Agomelatine;   Drug: Escitalopram
Outcome Measures: Change from baseline in markers of sympathetic nervous system activity.;   Change from baseline in the magnitude of morning surge in blood pressure.;   To determine the association between sympathetic nervous system activity and left ventricular hypertrophy.;   Change from baseline in insulin resistance.;   Change from baseline on markers of cardiac risk.
9 Unknown  Relapse Prevention With Escitalopram or Nortriptyline Following Electro-Convulsive Treatment (DUAG-7)
Condition: Major Depression
Interventions: Drug: escitalopram;   Drug: nortriptyline
Outcome Measures: Hamilton depression rating scale;   Drop out due to side-effects of drugs
10 Recruiting Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics
Condition: Alcohol Dependence
Intervention: Drug: citalopram
Outcome Measures: Craving for alcohol in type B alcohol dependence with citalopram compared to placebo;   Striatal dopamine receptor availability in type B alcohol dependence with citalopram, compared to placebo
11 Unknown  The Effects of Escitalopram on Cytokines
Condition: Depression
Intervention: Drug: Escitalopram
Outcome Measures: The changes in cytokines;   The changes in Hamilton Depression Rating Scale
12 Recruiting Brain Aging and Treatment Response in Geriatric Depression
Conditions: Mild Neurocognitive Disorder;   MCI;   Depression
Interventions: Drug: Escitalopram;   Drug: Memantine;   Drug: Placebo
Outcome Measures: Change in Hamilton Depression Rating Scale (HDRS) scores;   Change in cognitive domain scores
13 Unknown  Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning
Conditions: Depression;   Continuous Antidepressant Abuse;   Adverse Reaction to Drug
Intervention: Drug: Escitalopram
Outcome Measures: antidepressant response at 2,4,6,8 weeks A/E monitoring at 1,2,4,6,8 weeks;   biological value at 0 week and 8 weeks
14 Not yet recruiting The ISLAND Study: InSuLa Assessed Needs for Depression
Condition: Depression
Interventions: Drug: Escitalopram;   Behavioral: Cognitive Behavioral Therapy;   Other: Combination treatment (Escitalopram + CBT)
Outcome Measures: Remission from major depressive episode;   Response to treatment
15 Unknown  Citalopram for Cocaine Dependence
Condition: Cocaine Dependence
Interventions: Drug: Citalopram;   Drug: Placebo
Outcome Measures: Abstinence;   Cocaine Use Days;   Cocaine-negative Urines;   Retention in Treatment
16 Recruiting A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom
Condition: Depressive Disorder, Major
Intervention: Drug: Escitalopram
Outcome Measures: Change From Baseline in Quality of Life Enjoyment and Satisfaction Questionnaire, Short Form (Q-LES-Q-SF);   Change From Baseline in Sheehan Disability Scale (SDS);   Remission Rate at Week 8;   Onset of Effect Rate at Week 1;   Onset of Effect Rate at Week 2;   Change From Baseline to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Scores;   Change From Baseline to Week 8 in Hamilton Anxiety Scale (HAMA) Scores;   Change From Baseline to Week 8 in Inventory of Depressive Symptomatology, Self-Report (QIDS-SR) Scores
17 Unknown  Cipralex® for Anxiety Disorders in Adolescents
Condition: Anxiety Disorder
Intervention: Drug: Cipralex®
Outcome Measures: Treatment Efficacy;   Physiological response to stress;   Suicide risk
18 Recruiting Effects of Intravenous (IV) Citalopram on Emotional Brain Activity in Healthy Young and Elderly Adults
Condition: Healthy Young and Elderly Volunteers
Interventions: Drug: Intravenous Citalopram;   Drug: Normal Saline
Outcome Measures: BOLD fMRI Response;   Genetics and Cognitive/Emotional Change
19 Unknown  Cognitive Behavioural Analysis System of Psychotherapy (CBASp) Versus Escitalopram in Chronic Depression
Condition: Chronic Depression
Interventions: Other: CBASP psychotherapy;   Drug: Escitalopram
Outcome Measures: Depressive symptomatology after 8 weeks after randomization as measured by the MADRS;   Depressive symptoms and remission 28 weeks after randomization; social, interpersonal and work function 28 weeks after randomization
20 Unknown  Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy
Condition: Marijuana Dependence
Intervention: Drug: Escitalopram
Outcome Measures: Clean urine THC samples;   Questionnaire ratings of anxiety and depression and withdrawal symptoms